202 related articles for article (PubMed ID: 21254403)
1. Parachuting in the epigenome: the biology of gene vector insertion profiles in the context of clinical trials.
Baum C
EMBO Mol Med; 2011 Feb; 3(2):75-7. PubMed ID: 21254403
[TBL] [Abstract][Full Text] [Related]
2. Integration profile of retroviral vector in gene therapy treated patients is cell-specific according to gene expression and chromatin conformation of target cell.
Biasco L; Ambrosi A; Pellin D; Bartholomae C; Brigida I; Roncarolo MG; Di Serio C; von Kalle C; Schmidt M; Aiuti A
EMBO Mol Med; 2011 Feb; 3(2):89-101. PubMed ID: 21243617
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy for PIDs: progress, pitfalls and prospects.
Mukherjee S; Thrasher AJ
Gene; 2013 Aug; 525(2):174-81. PubMed ID: 23566838
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy of primary T cell immunodeficiencies.
Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M
Gene; 2013 Aug; 525(2):170-3. PubMed ID: 23583799
[TBL] [Abstract][Full Text] [Related]
5. Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy.
Cassani B; Montini E; Maruggi G; Ambrosi A; Mirolo M; Selleri S; Biral E; Frugnoli I; Hernandez-Trujillo V; Di Serio C; Roncarolo MG; Naldini L; Mavilio F; Aiuti A
Blood; 2009 Oct; 114(17):3546-56. PubMed ID: 19652199
[TBL] [Abstract][Full Text] [Related]
6. Strategies for retrovirus-based correction of severe, combined immunodeficiency (SCID).
Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M
Methods Enzymol; 2012; 507():15-27. PubMed ID: 22365767
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials.
Onodera M; Nelson DM; Sakiyama Y; Candotti F; Blaese RM
Acta Haematol; 1999; 101(2):89-96. PubMed ID: 10202239
[TBL] [Abstract][Full Text] [Related]
8. Recombinant adeno-associated virus-mediated gene transfer for the potential therapy of adenosine deaminase-deficient severe combined immune deficiency.
Silver JN; Elder M; Conlon T; Cruz P; Wright AJ; Srivastava A; Flotte TR
Hum Gene Ther; 2011 Aug; 22(8):935-49. PubMed ID: 21142972
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy for severe combined immunodeficiencies.
Gaspar HB; Thrasher AJ
Expert Opin Biol Ther; 2005 Sep; 5(9):1175-82. PubMed ID: 16120048
[TBL] [Abstract][Full Text] [Related]
10. Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity.
Wu C; Dunbar CE
Front Med; 2011 Dec; 5(4):356-71. PubMed ID: 22198747
[TBL] [Abstract][Full Text] [Related]
11. Genotoxicity of retroviral hematopoietic stem cell gene therapy.
Trobridge GD
Expert Opin Biol Ther; 2011 May; 11(5):581-93. PubMed ID: 21375467
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients.
Cooper AR; Lill GR; Shaw K; Carbonaro-Sarracino DA; Davila A; Sokolic R; Candotti F; Pellegrini M; Kohn DB
Blood; 2017 May; 129(19):2624-2635. PubMed ID: 28351939
[TBL] [Abstract][Full Text] [Related]
13. Ten years of gene therapy for primary immune deficiencies.
Aiuti A; Roncarolo MG
Hematology Am Soc Hematol Educ Program; 2009; ():682-9. PubMed ID: 20008254
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy for severe combined immunodeficiencies and beyond.
Fischer A; Hacein-Bey-Abina S
J Exp Med; 2020 Jan; 217(2):. PubMed ID: 31826240
[TBL] [Abstract][Full Text] [Related]
15. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.
Hacein-Bey-Abina S; Von Kalle C; Schmidt M; McCormack MP; Wulffraat N; Leboulch P; Lim A; Osborne CS; Pawliuk R; Morillon E; Sorensen R; Forster A; Fraser P; Cohen JI; de Saint Basile G; Alexander I; Wintergerst U; Frebourg T; Aurias A; Stoppa-Lyonnet D; Romana S; Radford-Weiss I; Gross F; Valensi F; Delabesse E; Macintyre E; Sigaux F; Soulier J; Leiva LE; Wissler M; Prinz C; Rabbitts TH; Le Deist F; Fischer A; Cavazzana-Calvo M
Science; 2003 Oct; 302(5644):415-9. PubMed ID: 14564000
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial.
Wang GP; Berry CC; Malani N; Leboulch P; Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Bushman FD
Blood; 2010 Jun; 115(22):4356-66. PubMed ID: 20228274
[TBL] [Abstract][Full Text] [Related]
17. Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug.
Ferrua F; Aiuti A
Hum Gene Ther; 2017 Nov; 28(11):972-981. PubMed ID: 28847159
[TBL] [Abstract][Full Text] [Related]
18. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy.
Aiuti A; Cassani B; Andolfi G; Mirolo M; Biasco L; Recchia A; Urbinati F; Valacca C; Scaramuzza S; Aker M; Slavin S; Cazzola M; Sartori D; Ambrosi A; Di Serio C; Roncarolo MG; Mavilio F; Bordignon C
J Clin Invest; 2007 Aug; 117(8):2233-40. PubMed ID: 17671653
[TBL] [Abstract][Full Text] [Related]
19. [Gene therapy for adenosine deaminase deficiency].
Sakiyama Y
Hokkaido Igaku Zasshi; 1996 Jan; 71(1):27-32. PubMed ID: 8727372
[TBL] [Abstract][Full Text] [Related]
20. Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies.
Silver JN; Flotte TR
Pharmacogenomics; 2008 Jul; 9(7):947-68. PubMed ID: 18597656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
